$创胜集团-B(06628.HK)$On October 9, the CDE website showed that The application for clinical trial of MBOS TST005 injection was accepted by the Food and Drug Administration, and the indication is solid tumor. TST005 is the second bi-functional anti-PD-L1 and TGF-β trap fusion protein to initiate a global clinical study.
创胜集团-B股票讨论区
bottom
bottom
high success rate
暂无评论